Lisa Earnhardt leads Intersect ENT (NASDAQ: XENT), a medical technology company dedicated to improving the quality of life for patients with ear, nose and throat conditions. She has led the company from 12 employees through the clinical stage, FDA approval, commercialization, IPO, to 2017 revenue of $96M and over 350 employees. Previously, she was President of Boston Scientific’s Cardiac Surgery division. Lisa has over two decades of experience in healthcare, primarily in leading global product launches and driving adoption of new medical technologies at both Boston Scientific and Guidant. She began her career at APM/CSC Healthcare where she provided management consulting services to healthcare provider organizations. Lisa serves on the boards of Intersect ENT and Nevro Corporation (NYSE: NVRO), a medical device company with a disruptive technology for treating chronic pain and other neuro disorders. She is a former Director of Kensey Nash (NASDAQ: KNSY, acquired by DSM in 2012). Lisa is a member of the board of directors of AdvaMed (Advanced Medical Technology Association) and the Kellogg Global Advisory Board. She received a Bachelor of Science in industrial engineering from Stanford University and an MBA from the Kellogg Graduate School of Management at Northwestern University.